Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Key Points and Investor-Relevant News

• Patent Developments:
  • U.S. Patent Notice of Allowance for CTx-1301: The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for Cingulate’s lead ADHD candidate, CTx-1301. Upon issuance, this patent will protect key aspects of CTx-1301’s formulation and method of use through May 2042. This strengthens Cingulate’s intellectual property portfolio and could support future market exclusivity.
  • European Patent Granted: Cingulate received a European patent (EP No. 22808184) for CTx-1301’s tri-modal, precision-timed pulsatile release profile, also extending protection through May 2042 in over 30 territories, including the UK.
• Regulatory Milestones:
  • New Drug Application (NDA) for CTx-1301: Submitted to the FDA in July 2025 for the treatment of ADHD in children and adults.
  • NDA Accepted for Review: FDA accepted the NDA in October 2025 under the 505(b)(2) regulatory pathway, assigning a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026.
  • Clinical Data: NDA supported by multiple clinical studies, including Phase 3 trials showing rapid onset and sustained efficacy in both adults and children. Large effect sizes were reported throughout the day, potentially addressing longstanding gaps in ADHD management.
  • FDA Requests: The FDA has requested additional information related to manufacturing and CMC (Chemistry, Manufacturing, and Controls) aspects. Importantly, these requests do not pertain to clinical safety or efficacy. The review timeline could be extended depending on the timing and scope of responses.
• Commercial Readiness:
  • Manufacturing Scale-Up: Commercial manufacturing is being scaled in preparation for launch, pending approval.
  • Market Access and Payer Engagement: Efforts underway to advance market access, payer engagement, and build commercial leadership.
  • Supply Chain Preparedness: Distribution and supply chain capabilities are being prepared.
  • Key Appointment: Bryan Downey named Chief Commercial Officer in November, bringing extensive commercialization experience from Alfasigma USA, Jubilant Pharma, and Sanofi.
• Capital Markets Activity:
  • \$12M PIPE Financing: Closed a \$12 million private investment in public equity (PIPE) in February 2026, led by Falcon Creek Capital Advisor LLC. Priced at-the-market under Nasdaq rules. All investors agreed to a 180-day lock-up, aligning interests ahead of regulatory milestones. Falcon Creek Capital gained the right to designate two board members; Jeff Hargroves was appointed.
• Financial Results
  • Cash Position: \$11.0 million in cash and cash equivalents as of December 31, 2025. The company expects current cash will last into late Q4 2026, primarily to support regulatory approval activities and pre-commercialization efforts for CTx-1301.
  • R&D Expenses: \$2.0 million for Q4 2025 (\$9.8 million for the year), up from \$4.3 million in Q4 2024 (\$9.4 million for the full year 2024). The increase is mainly from higher personnel, regulatory, and manufacturing costs, partially offset by lower clinical operations.
  • G&A Expenses: \$3.6 million for Q4 2025 (\$10.2 million for the year), up from \$1.9 million in Q4 2024 (\$6.2 million for the full year 2024), primarily due to increased pre-commercialization, personnel, legal, and professional fees.
  • Net Loss: \$6.3 million for Q4 2025 (\$22.4 million for the year), compared to \$6.2 million in Q4 2024 (\$16.6 million for the full year 2024). The larger net loss is mainly due to increased G&A expenses and interest on notes payable.
  • Balance Sheet Highlights:
    • Total assets: \$15.1 million (up from \$14.9 million)
    • Total liabilities: \$12.6 million (up from \$7.4 million)
    • Working capital: \$1.7 million (down from \$7.7 million)
    • Accumulated deficit: \$(132.4) million (up from \$(109.9) million)
    • Stockholders’ equity: \$2.5 million (down from \$7.5 million)
• Market Opportunity:
  • ADHD Market: U.S. ADHD market is approximately 100 million annual prescriptions. Over 20 million Americans diagnosed, with 12 million adults. Adult ADHD prevalence is growing faster than pediatric/adolescent segments.
  • CTx-1301 Product Details: Once-daily, multi-core tablet using proprietary PTR platform for three timed releases, targeting rapid onset and full-day efficacy. FDA review ongoing, with PDUFA target date May 31, 2026.

Potentially Price Sensitive Information

• Patent Allowance and Grant: Extension of patent protection to May 2042 in U.S. and Europe could significantly improve market exclusivity and future revenue potential.
• NDA Acceptance and PDUFA Date: FDA acceptance and assigned action date signals progress toward potential approval and commercialization. A positive or negative outcome on or around May 31, 2026, could materially affect share price.
• PIPE Financing: Successful \$12M financing, insider participation, and board appointment rights signal strong investor support but dilution risk.
• Cash Runway: Current cash expected to last into late Q4 2026, but increased expenses and net losses highlight need for future funding and potential dilution.
• FDA Requests: Additional manufacturing and CMC information requests may extend the review timeline but, so far, do not affect clinical safety or efficacy assessment.
• Commercial Launch Preparation: Ongoing commercial readiness and leadership hiring suggest anticipation of approval and launch, which could drive revenue and share price.

Conclusion

Cingulate Inc. is approaching a critical inflection point, with IP expansion, regulatory progress, commercial readiness, and recent capital markets activity positioning the company for potential growth. Investors should closely monitor the FDA review process for CTx-1301, patent developments, cash runway, and commercialization milestones. Any regulatory approval or denial, changes in FDA review timeline, or new financing could materially impact the share value.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investing in biopharmaceutical equities involves significant risks, including clinical, regulatory, and financial uncertainties. Please consult a qualified investment advisor and review Cingulate Inc.’s filings with the SEC, including risk factors, before making any investment decisions. The information provided is based on the latest available data and may change without notice.

View Cingulate Inc. Historical chart here